Tomasz Knurowski is the founder of CellCentric. CellCentric has raised $220M in total funding. Latest round: Series D.
Tomasz Knurowski is the CMO at CellCentric, a clinical-stage biotechnology company focused on developing inobrodib, a first-in-class, oral p300/CBP inhibitor for the treatment of multiple myeloma. The company is currently conducting a Phase 1/2 clinical trial for inobrodib and is supported by a global syndicate of life science investors.
Full founder directory · Investor directory · Company funding database · Fundraising library